Skip to content

VitalScan MCG Rule-out Multi-centre Pivotal Study - UK

A Prospective Multi-centre Observational Study to Evaluate the Diagnostic Accuracy of a Portable Magnetocardiograph Device for Acute Coronary Syndrome (ACS), Focusing on Rule-out Capability, in Patients Who Present to the Emergency Department With Chest Pain Symptoms Consistent With ACS.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02921438
Acronym
MAGNET-ACS
Enrollment
756
Registered
2016-10-03
Start date
2017-02-06
Completion date
2019-02-28
Last updated
2019-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Coronary Syndrome

Keywords

Cardiovascular Diseases, Heart Diseases, Myocardial Ischemia, NSTE ACS, NSTEMI, Unstable Angina Pectoris, Coronary Artery Disease

Brief summary

The study is a prospective multi-centre observational study to evaluate a portable magnetocardiograph device for the rule-out of acute coronary syndrome (ACS) in patients who present to the emergency department with chest pain and other symptoms consistent with ACS.

Detailed description

Few, if any, studies have evaluated the rule-out (R/O) of non-ST-segment elevation (NSTE) ACS which requires the sensitivity and negative predictive value (NPV) of the test to approach 100%. An alternative triage approach, utilizing a portable magnetocardiography (MCG) instrument in the emergency setting, may lead to a more accurate R/O for NSTEMI, UA, and clinically significant non-ACS coronary artery disease (CAD), in patients presenting to the ED with chest pain. MCG in the emergency setting is a new use of this non-invasive technique and may serve as an adjunctive aid that can improve cardiac triage for NSTE ACS and clinically significant CAD.This raises the research question of whether MCG may be useful for the early triage of patients with acute chest pain. In the study protocol, a clinical evaluation is defined that will assess the ability of a portable MCG instrument, using a fixed algorithm, to R/O ACS, with improved safety (i.e. \<\< 2% false negative rate) in patients presenting to an emergency setting with chest pain.

Interventions

A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.

Sponsors

Creavo Medical Technologies Ltd
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patient presents to the ED with chest pain syndrome of suspected cardiac origin (i.e. symptoms consistent with ACS) * 18+ year old male or female * Patient is willing and able to give written informed consent

Exclusion criteria

* ST-segment Elevation MI (STEMI) * Clear non-ischaemic cause for symptoms (e.g. trauma) * Haemodynamic instability on admission (e.g. BP\>220mmHg systolic & \>110mmHg diastolic, \<80mmHg systolic & \<40mmHg diastolic, HR\>160bpm) * Ventricular tachycardia or fibrillation that cannot be treated effectively * Atrial fibrillation * Thoracic metal implants * Pacemaker or internal defibrillator * Pregnancy (if after 20-week period)\* or lactation * Patient unable to lie down (i.e. supine position) or stay still on the examination bed * Patient unable to understand the informed consent process and/or has a poor understanding of English (e.g. English-speaking relative/translator not available) * Patient unable to comply with the requirements of the protocol

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity and specificity of MCGat discharge, 3 months follow-upSensitivity and specificity for diagnosing ACS, focusing on rule-out, in chest pain patients with normal sinus rhythm

Secondary

MeasureTime frame
Proportion of adverse events and typesat discharge, 3 months follow-up
All-cause mortality (divided into CV and non-CV causes) proportionthrough 1 week and 3 months follow-up
Change in sensitivity and specificity for diagnosing ACS, focusing on rule-out, in chest pain patients with normal sinus rhythm, according to low, intermediate and high PTP groupsat discharge, 3 months follow-up
MACE post-presentation to the ED (rule-out of ACS divided into MCG vs reference standard [adjudicated ACS/non-ACS diagnose])through 1 week and 3 months

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026